Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft- C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers

NCT04134143 is registered in ClinicalTrials.gov with Stratatech, a Mallinckrodt Company as lead sponsor.

NCT NCT04134143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04134143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft- C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers
Lead sponsor
Stratatech, a Mallinckrodt Company
Phase
Phase 1
Overall status
Terminated
Start date
November 7, 2019
Completion date
December 30, 2020
Enrollment
6 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetic foot ulcer, non-healing wound